Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells

Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells

Poly-(ADP)-ribose polymerase inhibitors (PARPi) and platinum-based drugs are promising therapies for triple negative breast cancers (TNBC) with BRCA1 or BRCA2 loss. PARPi(s) show better efficacies when combined with platinum-based therapy, however, acquisition of PARPi resistance has been linked wit...

Full description

Bibliographic Details
Main Authors: Ambikai Gajan, Ashapurna Sarma, Seongho Kim, Katherine Gurdziel, Gen Sheng Wu, Malathy P. Shekhar
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Oncology
Subjects:
PARP
acquired resistance
BRCA1
RNA-seq
γH2AX foci
RAD51
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.694793/full

Similar Items

Similar Items